SUBSCRIBE
SUBSCRIBE
News   Policy

Discovery Laboratories to File Surfaxin Response in 4 Weeks

September 24, 2008 | 
1 min read
Sept 24 (Reuters) - Discovery Laboratories Inc said it expects to submit a complete response to the U.S. Food and Drug Administration's concerns on its experimental lung drug for infants within the next four weeks.
Regulatory
MORE ON THIS TOPIC
Illustration of a yellow envelope on a blue background with a read warning symbol
GLP-1
Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Duchenne muscular dystrophy
Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
March 11, 2026
 · 
1 min read
 · 
Heather McKenzie
External view of the U.S. Capitol Building
Rare diseases
Senator Ron Johnson Launches Investigation Into FDA Rare Disease Rejections
March 10, 2026
 · 
3 min read
 · 
Heather McKenzie